Biologics Drug Market In Japan Gets Crowded With New Product Launches
This article was originally published in PharmAsia News
Following a June launch of Takeda Pharmaceutical's Vectibix (panitumumab) for colorectal cancer, more drug makers are planning new launches for biologics drugs in Japan
You may also be interested in...
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.
Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.